fbpx

$57M Austin Verdict: Biotech Defendant Considers Loss a ‘Win’

“The fact that the jury awarded only a small fraction of Ravgen’s damages claim—less than 15%—and rejected their willfulness claim is an indication that the jury correctly viewed Ravgen’s case as a huge overreach,” lead defense attorney Michael Summersgill said.

       

Related Articles

Responses

Your email address will not be published. Required fields are marked *